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To the Editor: Allen and colleagues2 provided an in-depth review of
the pathophysiology and functional outcomes of diabetic
polyneuropathy (DPN) among patients with diabetes mellitus (DM). As
explained,2 DPN often manifests in a symmetrical and lengthdependent pattern affecting distal portions of long peripheral nerves of
patients with DM,11 Here we highlight the molecular pathogenesis
within the soma of the motoneuron, which may also inform clinical
treatment. Although DPN manifests in neuronal axons, the deleterious
molecular cascade begins within the soma of the peripheral nerve
located within the anterior horn of the spinal cord. Glucose is
transported into the milieu of nervous tissue independent of insulin,5
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which results in a hyperglycemic metabolic milieu of nervous system
tissue in patients with DM. Excessive glucose is metabolized into
sorbitol and fructose, and both activate advanced glycation end
products (AGEs), resulting in molecular oxidative stress.3 Oxidative
stress within the soma triggers withdrawal of the longest (typically
most distal) nerve axons from their distal terminals without cellular
death.12 This observation is clinically relevant, because there is the
potential for recovery from structural damage to the axon before death
of the nerve soma.9 The precise mechanism by which oxidative stress
triggers distal axonal retraction is unclear but likely involves disruption
of sodium-potassium pump activity (Na+/K+-ATPase)10 and
downregulation of insulin-like growth factor 1 (IGF-1),8 leading to
disruption of the neuromuscular junction. Consequently, denervation
of distal muscle fibers occurs and the soma signals lateral sprouting of
the retracted distal axon to innervate more proximal muscle fibers.4
The net result is a loss of motor unit numbers,12 an increase in the size
of surviving motor units,12 and subsequent reduction of maximal
muscle force1 and control of muscle force.
The distinction between the pathogenesis beginning within the
neuronal axon or soma could have important implications for clinical
interventions. For example, the nerve soma could be targeted with
interventions (e.g., pharmacological) to preserve the function of the
neuron. Clinically, the most sensitive tools identified to date for
assessing DPN-related impairments of neuromuscular function
(compared with DM patients without DPN) are isometric strength of
distal muscles (e.g., plantar and dorsiflexors)1,6 and the timed up and
go (TUG) test.7 Thus the molecular underpinnings of DPN are likely
related to the functional outcomes discussed by Allen and colleagues,2
and further understanding the involved mechanisms may help guide
clinical practice.
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